Bouchon, A., Dietrich, J. & Colonna, M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164, 4991–4995 (2000).
Kasamatsu, J. et al. Double-stranded RNA analog and type I interferon regulate expression of Trem paired receptors in murine myeloid cells. BMC Immunol. 17, 9 (2016).
Stet, R. J. et al. Novel immunoglobulin-like transcripts in teleost fish encode polymorphic receptors with cytoplasmic ITAM or ITIM and a new structural Ig domain similar to the natural cytotoxicity receptor NKp44. Immunogenetics 57, 77–89 (2005).
Viertlboeck, B. C., Schmitt, R. & Gobel, T. W. The chicken immunoregulatory receptor families SIRP, TREM, and CMRF35/CD300L. Immunogenetics 58, 180–190 (2006).
Clark, G. J., Green, B. J. & Hart, D. N. The CMRF-35H gene structure predicts for an independently expressed member of an ITIM/ITAM pair of molecules localized to human chromosome 17. Tissue Antigens 55, 101–109 (2000).
Green, B. J., Clark, G. J. & Hart, D. N. The CMRF-35 mAb recognizes a second leukocyte membrane molecule with a domain similar to the poly Ig receptor. Int. Immunol. 10, 891–899 (1998).
Jackson, D. G., Hart, D. N., Starling, G. & Bell, J. I. Molecular cloning of a novel member of the immunoglobulin gene superfamily homologous to the polymeric immunoglobulin receptor. Eur. J. Immunol. 22, 1157–1163 (1992).
Aguilar, H. et al. Molecular characterization of a novel immune receptor restricted to the monocytic lineage. J. Immunol. 173, 6703–6711 (2004).
Chung, D. H. et al. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J. Immunol. 171, 6541–6548 (2003).
Barrow, A. D., Martin, C. J. & Colonna, M. The natural cytotoxicity receptors in health and disease. Front. Immunol. 10, 909 (2019).
Lanier, L. L. DAP10- and DAP12-associated receptors in innate immunity. Immunol. Rev. 227, 150–160 (2009).
Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell 170, 649–663 (2017).
Otero, K. et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and β-catenin. Nat. Immunol. 10, 734–743 (2009).
Tessarz, A. S. et al. Non-T cell activation linker (NTAL) negatively regulates TREM-1/DAP12-induced inflammatory cytokine production in myeloid cells. J. Immunol. 178, 1991–1999 (2007).
Yuan, Z. et al. Triggering receptor expressed on myeloid cells 1 (TREM-1)-mediated Bcl-2 induction prolongs macrophage survival. J. Biol. Chem. 289, 15118–15129 (2014).
Mocsai, A., Zhou, M., Meng, F., Tybulewicz, V. L. & Lowell, C. A. Syk is required for integrin signaling in neutrophils. Immunity 16, 547–558 (2002).
Mocsai, A. et al. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat. Immunol. 7, 1326–1333 (2006).
Turnbull, I. R. et al. Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177, 3520–3524 (2006).
Hamerman, J. A., Tchao, N. K., Lowell, C. A. & Lanier, L. L. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat. Immunol. 6, 579–586 (2005).
Peng, Q., Long, C. L., Malhotra, S. & Humphrey, M. B. A physical interaction between the adaptor proteins DOK3 and DAP12 is required to inhibit lipopolysaccharide signaling in macrophages. Sci. Signal. 6, ra72 (2013).
Peng, Q. et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci. Signal. 3, ra38 (2010).
Wang, S. et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell 185, 4153–4169 (2022). This paper shows that TREM2 signals through both DAP12-dependent and DAP10-dependent pathways.
Chang, C. et al. Cutting edge: KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties. J. Immunol. 163, 4651–4654 (1999).
Upshaw, J. L. et al. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 7, 524–532 (2006).
Bouchon, A., Facchetti, F., Weigand, M. A. & Colonna, M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410, 1103–1107 (2001).
Bleharski, J. R. et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J. Immunol. 170, 3812–3818 (2003).
Netea, M. G. et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. J. Leukoc. Biol. 80, 1454–1461 (2006).
Gibot, S. et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J. Exp. Med 200, 1419–1426 (2004).
Wang, F. et al. Blocking TREM-1 signaling prolongs survival of mice with Pseudomonas aeruginosa induced sepsis. Cell Immunol. 272, 251–258 (2012).
Turnbull, I. R. et al. DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis. J. Exp. Med 202, 363–369 (2005).
Klesney-Tait, J. et al. Transepithelial migration of neutrophils into the lung requires TREM-1. J. Clin. Invest. 123, 138–149 (2013).
Baruah, S. et al. TREM-1 regulates neutrophil chemotaxis by promoting NOX-dependent superoxide production. J. Leukoc. Biol. 105, 1195–1207 (2019).
Hommes, T. J. et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) improves host defence in pneumococcal pneumonia. J. Pathol. 233, 357–367 (2014).
Lagler, H. et al. TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during pneumococcal pneumonia. J. Immunol. 183, 2027–2036 (2009).
Lin, Y. T. et al. TREM-1 promotes survival during Klebsiella pneumoniae liver abscess in mice. Infect. Immun. 82, 1335–1342 (2014).
Weber, B. et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathog. 10, e1003900 (2014).
Gingras, M. C., Lapillonne, H. & Margolin, J. F. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol. Immunol. 38, 817–824 (2002).
Baruah, S. et al. Identification of a novel splice variant isoform of TREM-1 in human neutrophil granules. J. Immunol. 195, 5725–5731 (2015).
Begum, N. A. et al. Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages. Infect. Immun. 72, 937–948 (2004).
Gomez-Pina, V. et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J. Immunol. 179, 4065–4073 (2007).
Gibot, S. et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N. Engl. J. Med. 350, 451–458 (2004).
Su, L., Liu, D., Chai, W., Liu, D. & Long, Y. Role of sTREM-1 in predicting mortality of infection: a systematic review and meta-analysis. BMJ Open 6, e010314 (2016).
Forrester, D. L., Barr, H. L., Fogarty, A. & Knox, A. sTREM-1 is elevated in cystic fibrosis and correlates with proteases. Pediatr. Pulmonol. 52, 467–471 (2017).
de Nooijer, A. H. et al. Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. Biosci. Rep. 41, BSR20210940 (2021).
Van Singer, M. et al. COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department. J. Allergy Clin. Immunol. 147, 99–106 (2021).
Francois, B. et al. Nangibotide in patients with septic shock: a phase 2a randomized controlled clinical trial. Intensive Care Med 46, 1425–1437 (2020).
Murakami, Y. et al. Induction of triggering receptor expressed on myeloid cells 1 in murine resident peritoneal macrophages by monosodium urate monohydrate crystals. Arthritis Rheum. 54, 455–462 (2006).
Nochi, H. et al. Modulation of hepatic granulomatous responses by transgene expression of DAP12 or TREM-1-Ig molecules. Am. J. Pathol. 162, 1191–1201 (2003).
Nguyen-Lefebvre, A. T. et al. The innate immune receptor TREM-1 promotes liver injury and fibrosis. J. Clin. Invest 128, 4870–4883 (2018). This paper demonstrates that TREM1 is a master regulator of Kupffer cell activation.
Zysset, D. et al. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat. Commun. 7, 13151 (2016).
Boufenzer, A. et al. TREM-1 mediates inflammatory injury and cardiac remodeling following myocardial infarction. Circ. Res. 116, 1772–1782 (2015).
Vandestienne, M. et al. TREM-1 orchestrates angiotensin II-induced monocyte trafficking and promotes experimental abdominal aortic aneurysm. J. Clin. Invest. 131, e142468 (2021).
Liu, Q. et al. Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity. Nat. Immunol. 20, 1023–1034 (2019). This report shows that TREM1 amplifies inflammation in response to both brain-derived and intestinal-derived components during stroke.
Tammaro, A. et al. TREM1/3 deficiency impairs tissue repair after acute kidney injury and mitochondrial metabolic flexibility in tubular epithelial cells. Front. Immunol. 10, 1469 (2019).
Schenk, M., Bouchon, A., Seibold, F. & Mueller, C. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J. Clin. Invest. 117, 3097–3106 (2007).
Park, J. J. et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig. Dis. Sci. 54, 1525–1531 (2009).
Tzivras, M. et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J. Gastroenterol. 12, 3416–3419 (2006).
留言 (0)